Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Glioblastoma 405Brain Neoplasms 163Glioma 159Gliosarcoma 128Astrocytoma 115Central Nervous System Neoplasms 110Oligodendroglioma 74Neuroblastoma 44Medulloblastoma 33Ependymoma 26Recurrence 23Neoplasms 19Neoplasm Metastasis 16Diffuse Intrinsic Pontine Glioma 15Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Melanoma 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10Lymphoma 9Familial ependymoma 9Rhabdomyosarcoma 8Osteosarcoma 8Neuroectodermal Tumors, Primitive 8Breast Neoplasms 8Sarcoma, Ewing 6Sarcoma 6Pinealoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Glioma, Subependymal 6

Interventions

Temozolomide 1Surveys and Questionnaires 1Microarray Analysis 1DNA Methylation 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Growth Hormone-Secreting Pituitary Adenoma × Temozolomide × CNS × Clear all
NCT00601289 2020-07-31

Temozolomide in Treating Patients With Invasive Pituitary Tumors

Jonsson Comprehensive Cancer Center

Phase 2 Withdrawn
CNSEndocrine

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡